Xilio Therapeutics (XLO) Free Cash Flow (2020 - 2026)

Xilio Therapeutics has disclosed Free Cash Flow across 7 years of filings, most recently posting -$22.9 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$22.9 million, down 179.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$57.1 million (down 374.56% YoY), and the FY2025 annual result was -$5.5 million, up 70.08% from the prior year.
• Free Cash Flow came in at -$22.9 million for Q1 2026 at Xilio Therapeutics, down from -$2.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $28.7 million in Q1 2025 to a low of -$25.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$14.6 million (2025), against an average of -$11.3 million.
• Across the five-year window, Free Cash Flow surged 372.6% in 2025 and sank 179.83% in 2026, its largest moves.
• Xilio Therapeutics' Free Cash Flow stood at -$17.9 million in 2022, then increased by 24.87% to -$13.4 million in 2023, then declined by 5.48% to -$14.2 million in 2024, then surged by 85.22% to -$2.1 million in 2025, then sank by 994.08% to -$22.9 million in 2026.
• The last three Free Cash Flow figures came in at -$22.9 million (Q1 2026), -$2.1 million (Q4 2025), and -$17.5 million (Q3 2025), per Business Quant data.